Developer docs
API playgroundTry for free, no card

Search company profiles

Oxipit

Full company profile

uuid000245r

Namestring
Oxipit
Legal namestring
Oxipit, UAB
Websiteurl
oxipit.ai
Company typeenum
Private
Founded yearint
2017
Descriptiontext

Oxipit is a Vilnius, Lithuania-based medical imaging AI company founded in 2017 that develops CE-certified deep learning software for radiology workflows. Its portfolio spans three suites: the CXR Suite (chest X-ray), CT Suite, and MSK Suite, covering detection of 75+ chest X-ray findings, chest CT analysis for pulmonary embolism and lung lesions, and musculoskeletal X-ray fracture detection. The company's flagship product, ChestLink, is the world's first and only CE Class IIb-certified autonomous AI for healthy chest X-ray reporting, operating with 99.9% sensitivity to remove normal studies from radiologist worklists without human review. Complementary products include ChestEye CAD with triage, CT Eye, MSK Eye, and an NLP-based quality assurance tool that cross-references radiologist reports with AI findings to detect missed pathology.

The company generates revenue primarily through enterprise software licenses and subscriptions sold to hospitals, diagnostic imaging centers, public health clinics, and radiology service providers, distributed through direct enterprise sales supplemented by AI marketplaces (deepcOS, CARPL, Blackford) and regional distributors in Africa and Latin America. Oxipit holds CE, ANVISA (Brazil), and TGA (Australia) certifications, with deployments in 30+ countries and over 1.5 million cases processed in 2024, nearly 3x the 2023 volume. In April 2026, Oxipit was acquired by Swedish medical imaging IT company Sectra, becoming a dedicated AI development center within Sectra's Imaging IT Solutions division with access to Sectra's enterprise imaging customer base across 19 countries.

Short descriptiontext

Oxipit develops CE-certified AI medical imaging software for chest X-ray, chest CT, and musculoskeletal workflows, including the world's first CE Class IIb-certified autonomous chest X-ray reporting AI. Now part of Sectra after April 2026 acquisition.

Operating statusenum
Acquired
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersVilnius, Lithuania
HQ citystring
Vilnius
HQ countrystring
Lithuania
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
radiology AI software, medical imaging AI, chest X-ray analysis, autonomous radiology reporting, diagnostic imaging AI
Industry6 codes
PRIMARYHLAHABAJ
Radiology AI, CAD & Advanced Visualization Software
Healthcare & Life Sciences/Medical Devices & Diagnostics/Medical Imaging & Radiology Equipment
SECONDARYHLACALAG
AI Orchestration & Imaging Analytics Platforms (Model Management/Triage)
Healthcare & Life Sciences/Digital Health & Health IT/Medical Imaging Informatics (PACS/RIS/VNA) & Radiology IT
SECONDARYHLACALAL
Quality, Peer Review & Compliance Tools (MQSA/ACR/QA)
Healthcare & Life Sciences/Digital Health & Health IT/Medical Imaging Informatics (PACS/RIS/VNA) & Radiology IT
SECONDARYHLACALAF
Radiology Reporting, Dictation & Structured Reporting
Healthcare & Life Sciences/Digital Health & Health IT/Medical Imaging Informatics (PACS/RIS/VNA) & Radiology IT
SECONDARYHDAAAEAH
Medical Imaging AI
SECONDARYHLAAALAO
Digital & AI-Enabled Diagnostics (algorithmic interpretation, decision support tied to assays)
NAICS code1 code
  • Software Publishers5132
SIC code1 code
  • Services-Prepackaged Software7372
Product category
Radiology AI Software
Social media profiles2 records
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model2 records
1AI Medical Imaging Software Licenses
TypeSubscription Recurring
Description

Oxipit generates revenue primarily through licensing its CE-certified medical imaging AI software (ChestLink, ChestEye, CT Eye, MSK Eye) to healthcare providers. Sales are structured as enterprise subscriptions or usage-based licenses, typically contracted through the company's own sales team or channel partners. Following acquisition by Sectra in April 2026, Oxipit operates as a dedicated AI development center within Sectra's Imaging IT Solutions operating area, with revenue flowing through Sectra's commercial infrastructure.

oxipit.ai
2Platform Marketplace Distribution
TypeSubscription Recurring
Description

Oxipit generates revenue through marketplace and platform partnerships including deepcOS, CARPL, and Blackford. These partners distribute Oxipit solutions to their customer bases, with revenue shared through platform fees or per-study usage arrangements.

oxipit.ai
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels9 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Technology or R&D, Personnel, Marketing or Sales, Operations
Pricing details1 tier
1Enterprise licensing — pricing not publicly disclosed
ModelSubscriptionBilling cadenceAnnual
Notes

No public pricing listed. Sales conducted through direct enterprise sales, channel partners, and AI marketplaces. Annual contracts likely standard for healthcare institutions.

oxipit.ai
GTM typeB2B
B2B
Offering typeSoftware
Software
Brand1 of 5 records shown
1CXR Suite
Description

AI suite for chest X-ray workflows including ChestLink autonomous AI, ChestEye CAD, and Quality assurance tools supporting 75 findings.

oxipit.ai
+4 more records
Core offering1 text field

Oxipit develops CE-certified AI software for radiology, offering autonomous chest X-ray reporting (ChestLink), computer-aided detection of 75+ radiological findings (ChestEye), real-time quality assurance (ChestEye Quality), chest CT analysis (CT Eye), and musculoskeletal X-ray analysis (MSK Eye). Solutions integrate directly into existing PACS/RIS environments of hospitals, radiology departments, and diagnostic imaging networks to automate routine reporting, prioritize urgent cases, and flag missed findings. The company sells through direct enterprise sales, AI marketplaces, and regional distributors, and operates as a dedicated AI development center within Sectra following its April 2026 acquisition.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 9 values shown
  • Automates up to 40% of chest X-ray reporting workflow in general hospitals; up to 80% in preventive health check settings
+8 more records
Product overview1 text field

Oxipit offers three comprehensive AI suites covering chest X-ray, chest CT, and musculoskeletal imaging. The CXR Suite is the flagship portfolio combining three modules: ChestLink (world's first CE Class IIb certified autonomous AI for normal chest X-ray reporting with 99.9% sensitivity), ChestEye (CAD detecting 75 radiological findings with triage), and ChestEye Quality (real-time QA using NLP to detect missed findings). The CT Suite and MSK Suite extend this workflow-integrated AI approach into chest CT and musculoskeletal imaging respectively. All solutions are designed to integrate directly into existing PACS environments and support radiologists from study arrival through final report.

Product and service8 records
1CXR Suite
CategoryRadiology AI Software — Chest X-ray
Description

Comprehensive chest X-ray AI suite combining ChestLink (autonomous reporting), ChestEye (CAD for 75 findings detection), and ChestEye Quality (real-time QA). Offers four workflow tiers from basic decision support to full autonomy for normal chest X-rays. Designed for hospitals, radiology departments, and diagnostic imaging centers.

2ChestLink
CategoryRadiology AI Software — Autonomous Reporting
Description

World's first and only CE Class IIb certified autonomous AI for healthy chest X-ray reporting. Automatically identifies high-confidence normal examinations with 99.9% sensitivity and generates final reports without radiologist involvement, removing them from the radiologist worklist. Can automate up to 40% of chest X-ray workflow in general hospital settings and up to 80% in preventive health check settings.

3ChestEye
CategoryRadiology AI Software — Computer-Aided Detection
Description

AI CAD application that detects 75 common radiological findings in chest X-rays with an average AUC of 93%, including localization of suspicious areas and preliminary reporting. Includes a triage feature to prioritize time-sensitive cases. Targets hospitals and radiology departments seeking AI-assisted detection.

4ChestEye Quality
CategoryRadiology AI Software — Quality Assurance
Description

AI-powered second-reader quality assurance tool that analyzes medical images and radiologist reports to prevent diagnostic errors. Uses NLP to cross-reference radiologist findings with AI-identified findings, alerting radiologists to missed findings in near-real time. Works with chest X-ray, MSK X-ray, mammography, and CT images.

5CT Suite
CategoryRadiology AI Software — Chest CT
Description

Chest CT AI suite powered by CT Eye for detection, prioritization, and quality assurance. Assists radiologists in identifying pulmonary embolism, lung lesions, and lung consolidation in adult chest CT studies, with study prioritization and automated post-report quality checks. Designed for hospitals and radiology departments handling chest CT workflows.

6CT Eye
CategoryRadiology AI Software — Chest CT
Description

CE-certified AI tool for chest CT imaging that supports radiologists in detecting pulmonary embolism, lung lesions, and lung consolidation. Provides study prioritization and automated post-report quality checks using NLP to compare AI findings with radiologist reports.

7MSK Suite
CategoryRadiology AI Software — Musculoskeletal
Description

Musculoskeletal X-ray AI suite powered by MSK Eye for fracture detection and quality assurance. Supports radiologists in identifying fractures, arthritis, osteoporosis, bone lesions, and other skeletal abnormalities across high-volume musculoskeletal imaging workflows.

8MSK Eye
CategoryRadiology AI Software — Musculoskeletal
Description

CE-certified AI tool for high-volume musculoskeletal X-ray reporting supporting findings such as fractures, dislocations, degenerative changes, arthritis, osteoporosis, bone lesions, and post-surgical findings. Includes triage prioritization and automated post-report quality checks.

Scale indicator7 records

Each record includes

Type, Value, Description, Source

Partnership13 partners
Strategic tierFlagshipTypeOEM/ Whitelabel/ Licensing PartnerAnnounced on2026-04-15
Description

Swedish medical imaging IT company Sectra completed the acquisition of Oxipit in April 2026 (agreement announced March 5, 2026). Oxipit operates as a dedicated AI development center within Sectra's Imaging IT Solutions operating area. Sectra gains ownership of ChestLink (first CE Class IIB-certified autonomous chest X-ray AI), CT Eye, and MSK Eye. The acquisition strengthens Sectra's vendor-neutral AI marketplace and broadens its AI portfolio for diagnostic imaging. Sectra paid upfront cash consideration plus contingent consideration tied to commercial and regulatory milestones.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-03-03
Description

The German Medical Institute in Cyprus selected Oxipit as its chest X-ray AI partner following a structured clinical evaluation of three leading vendors across 700+ real-world cases. Oxipit CXR Suite was chosen for pathology detection (CAD), smart triage, and semi-autonomous pre-populated reports, integrated via Newton's Tree PACS platform.

Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2025-11-18
Description

One of Austria's largest private radiology providers (275,000+ patients annually) selected Oxipit CXR Suite after rigorous multi-vendor evaluation on its own retrospective dataset. Deployment via deepc integration platform. Diagnostikum noted Oxipit's strongest overall performance for their outpatient setting where the majority of exams are normal.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-06-05
Description

Norway's first pilot project for AI-powered thoracic X-ray imaging, led by Vestre Viken as part of a national AI procurement coordinated with Sykehuspartner and other regional health authorities. The pilot evaluates ChestLink in supervised mode with the goal of advancing toward autonomous clinical use. Vestre Viken represents a structured, multidisciplinary approach to AI implementation in clinical practice.

Strategic tierFlagshipTypeChannel Partner/ Reseller/ DistributorAnnounced on2025-02-17
Description

European diagnostic services provider Unilabs selected Oxipit to deploy ChestLink and ChestEye throughout its European network following a comprehensive international evaluation process. Initial rollout starts in Portugal with option to extend across all Unilabs operations in Europe. Oxipit's AI streamlines chest X-ray reporting through automated triage and second-reading capabilities.

Strategic tierCoreTypeTechnology or IntegrationAnnounced on2024-06-25
Description

Partnership integrates Oxipit's ChestLink, ChestEye, and ChestEye Quality into the deepcOS radiology AI platform. Healthcare institutions access Oxipit solutions through a single contract, billing, service, and support framework with full data protection and cybersecurity compliance.

Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2024-04-01
Description

FIDI, one of Latin America's largest radiology service providers (400,000+ studies/month across 90+ sites in Brazil), deployed Oxipit's chest X-ray AI in emergency departments via the CARPL platform integrated with Philips Vue PACS. AI-generated annotations appear directly on images, supporting ER physicians who lack real-time radiologist access. Reduced turnaround times from 1 hour to 5 minutes at some sites.

Strategic tierCoreTypeTechnology or IntegrationAnnounced on2023-11-22
Description

Blackford, a strategic radiology AI platform with 100+ applications, integrates Oxipit's Quality application into its enterprise AI platform. Provides radiologists with an always-on AI second reader that flags potential missed findings by cross-referencing radiologist reports with AI image analysis.

Strategic tierCoreTypeTechnology or IntegrationAnnounced on2023-03-02
Description

CARPL platform, the world's only US FDA-cleared and CE-marked vendor-neutral AI platform, makes Oxipit's full product portfolio available to healthcare institutions globally. CARPL provides single-user interface, single data channel, and single procurement channel for testing, deployment, and monitoring of Oxipit AI in clinical workflows.

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2022-04-26
Description

Oxipit and AstraZeneca conducted a joint pilot study deploying ChestEye Quality AI for improved pulmonary nodule detection in two major primary care centers in Lithuania. Analysis of nearly 50,000 chest X-ray images in 2021 detected 82 additional clinically relevant nodule findings, potentially identifying additional early instances of lung cancer.

Strategic tierMinorTypeChannel Partner/ Reseller/ DistributorAnnounced on2021-01-12
Description

Nairobi-based Parasmed, founded by a senior radiologist from Oulu University Hospital (Finland), distributes Oxipit CXR AI products across Eastern Africa. Before commercial deployment, Parasmed partners with local high-level medical institutions to evaluate software performance using real-world clinical data, demonstrating AI workflow to local institutions.

12Teleradiología de Colombia
Strategic tierMinorTypeChannel Partner/ Reseller/ DistributorAnnounced on2020-08-24
Description

Leading diagnostic imaging services provider in Colombia rolling out Oxipit AI solutions across its network, marking the first Oxipit deployment in Colombia with more announcements expected in Latin America.

oxipit.ai
Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2020-01-06
Description

Swiss medical distribution company Healthcare Konnect distributes Oxipit's ChestEye AI imaging suite to healthcare institutions in Nigeria. Partnership aims to improve detection of 75 pathologies including tuberculosis in one of Africa's largest markets, addressing severe radiologist shortages (only ~400 specialists for the entire population).

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Qure.ai is a leading AI radiology company with chest X-ray and head CT solutions (qXR, qER). It competes directly with Oxipit in autonomous and CAD chest X-ray AI, with similar target customers and global deployments.

TypeDirect peer
Description

Lunit develops AI for chest X-ray (Lunit INSIGHT CXR) and mammography, with FDA-cleared and CE-marked products. Directly comparable to Oxipit's CXR Suite in terms of modality, customer base, and go-to-market.

TypeDirect peer
Description

Aidoc provides AI-driven triage and detection across CT and X-ray modalities. Overlaps with Oxipit's CT Eye and triage features, serving similar hospital and radiology department customers.

TypeBroad incumbent
Description

Siemens Healthineers offers AI-Rad Companion and other radiology AI embedded within its enterprise imaging solutions. Represents a broad incumbent competitor that bundles AI with PACS, similar to how Sectra now bundles Oxipit.

TypeDirect peer
Description

Annalise.ai offers a comprehensive AI platform detecting 130+ findings on chest X-rays. Directly competes with Oxipit's ChestEye (75 findings) and targets similar radiology workflows globally.

TypeOthers
Description

Blackford operates a vendor-neutral enterprise AI platform for radiology with 100+ apps. It is both a distribution partner for Oxipit's Quality application and an indirect competitor via other AI offerings on its platform.

TypeBroad incumbent
Description

Philips integrates AI imaging applications within its Vue PACS and enterprise imaging portfolio (e.g., Philips Algorithm Marketplace). Competes indirectly via platform partnerships where Oxipit is also deployed (e.g., FIDI/Philips Vue PACS).

TypeDirect peer
Description

VUNO develops AI medical imaging solutions including chest X-ray (VUNO Med-Chest X-ray) and CT. Comparable to Oxipit's portfolio in modality coverage and global commercial expansion in Asia and beyond.

TypeDirect peer
Description

Delft Imaging develops AI for chest X-ray screening, particularly for tuberculosis. Comparable to Oxipit's emerging-market deployments (Nigeria, Eastern Africa) addressing similar radiologist-shortage problems.

TypeEmerging player
Description

contextflow offers AI for CT imaging (SEARCH Lung CT). Already a partnership collaborator with Oxipit at Leiden UMC for combined CT quality assurance, addressing similar clinical use cases.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers8 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

Integration4 records

Each record includes

Title, Type, Description, Source

AI capability7 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature7 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles11 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance8 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds3 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors5 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Oxipit

Radiology AI Softwareoxipit.ai

Oxipit develops CE-certified AI medical imaging software for chest X-ray, chest CT, and musculoskeletal workflows, including the world's first CE Class IIb-certified autonomous chest X-ray reporting AI. Now part of Sectra after April 2026 acquisition.

What Oxipit does

Oxipit is a Vilnius, Lithuania-based medical imaging AI company founded in 2017 that develops CE-certified deep learning software for radiology workflows. Its portfolio spans three suites: the CXR Suite (chest X-ray), CT Suite, and MSK Suite, covering detection of 75+ chest X-ray findings, chest CT analysis for pulmonary embolism and lung lesions, and musculoskeletal X-ray fracture detection. The company's flagship product, ChestLink, is the world's first and only CE Class IIb-certified autonomous AI for healthy chest X-ray reporting, operating with 99.9% sensitivity to remove normal studies from radiologist worklists without human review. Complementary products include ChestEye CAD with triage, CT Eye, MSK Eye, and an NLP-based quality assurance tool that cross-references radiologist reports with AI findings to detect missed pathology.

The company generates revenue primarily through enterprise software licenses and subscriptions sold to hospitals, diagnostic imaging centers, public health clinics, and radiology service providers, distributed through direct enterprise sales supplemented by AI marketplaces (deepcOS, CARPL, Blackford) and regional distributors in Africa and Latin America. Oxipit holds CE, ANVISA (Brazil), and TGA (Australia) certifications, with deployments in 30+ countries and over 1.5 million cases processed in 2024, nearly 3x the 2023 volume. In April 2026, Oxipit was acquired by Swedish medical imaging IT company Sectra, becoming a dedicated AI development center within Sectra's Imaging IT Solutions division with access to Sectra's enterprise imaging customer base across 19 countries.

Oxipit firmographics

Firmographics
Name
Oxipit
Legal name
Oxipit, UAB
Website
https://oxipit.ai
Company type
Private
Founded year
2017
Operating status
Acquired
Headcount range
11–50 employees
Short description
Oxipit develops CE-certified AI medical imaging software for chest X-ray, chest CT, and musculoskeletal workflows, including the world's first CE Class IIb-certified autonomous chest X-ray reporting AI. Now part of Sectra after April 2026 acquisition.
Ownership category
akta.pro rank

Oxipit industry classification

Industry
Product category
Radiology AI Software
NAICS
Software Publishers (5132)
SIC
Services-Prepackaged Software (7372)
akta.pro industry
PRIMARYHLAHABAJ
Radiology AI, CAD & Advanced Visualization Software
Healthcare & Life Sciences/Medical Devices & Diagnostics/Medical Imaging & Radiology Equipment
SECONDARYHLACALAG
AI Orchestration & Imaging Analytics Platforms (Model Management/Triage)
Healthcare & Life Sciences/Digital Health & Health IT/Medical Imaging Informatics (PACS/RIS/VNA) & Radiology IT
SECONDARYHLACALAL
Quality, Peer Review & Compliance Tools (MQSA/ACR/QA)
Healthcare & Life Sciences/Digital Health & Health IT/Medical Imaging Informatics (PACS/RIS/VNA) & Radiology IT
SECONDARYHLACALAF
Radiology Reporting, Dictation & Structured Reporting
Healthcare & Life Sciences/Digital Health & Health IT/Medical Imaging Informatics (PACS/RIS/VNA) & Radiology IT
SECONDARYHDAAAEAH
Medical Imaging AI
SECONDARYHLAAALAO
Digital & AI-Enabled Diagnostics (algorithmic interpretation, decision support tied to assays)

Keywords

  • Radiology AI software
  • Medical imaging AI
  • Chest X-ray analysis
  • Autonomous radiology reporting
  • Diagnostic imaging AI

Where Oxipit is headquartered

Location

Headquarters

HQ city
Vilnius
HQ country
Lithuania
HQ region
Europe

Offices1 record

Markets served

Oxipit business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Technology or R&D, Personnel, Marketing or Sales, Operations

Revenue model

  1. AI Medical Imaging Software Licenses: Oxipit generates revenue primarily through licensing its CE-certified medical imaging AI software (ChestLink, ChestEye, CT Eye, MSK Eye) to healthcare providers. Sales are structured as enterprise subscriptions or usage-based licenses, typically contracted through the company's own sales team or channel partners. Following acquisition by Sectra in April 2026, Oxipit operates as a dedicated AI development center within Sectra's Imaging IT Solutions operating area, with revenue flowing through Sectra's commercial infrastructure.
  2. Platform Marketplace Distribution: Oxipit generates revenue through marketplace and platform partnerships including deepcOS, CARPL, and Blackford. These partners distribute Oxipit solutions to their customer bases, with revenue shared through platform fees or per-study usage arrangements.

Pricing tiers

ModelBillingPrice
SubscriptionAnnualEnterprise licensing — pricing not publicly disclosed

Go-to-market motion3 records

Distribution channels9 records

Marketing channels6 records

Oxipit product offering

Product offering

Core offering

Oxipit develops CE-certified AI software for radiology, offering autonomous chest X-ray reporting (ChestLink), computer-aided detection of 75+ radiological findings (ChestEye), real-time quality assurance (ChestEye Quality), chest CT analysis (CT Eye), and musculoskeletal X-ray analysis (MSK Eye). Solutions integrate directly into existing PACS/RIS environments of hospitals, radiology departments, and diagnostic imaging networks to automate routine reporting, prioritize urgent cases, and flag missed findings. The company sells through direct enterprise sales, AI marketplaces, and regional distributors, and operates as a dedicated AI development center within Sectra following its April 2026 acquisition.

Product overview

Oxipit offers three comprehensive AI suites covering chest X-ray, chest CT, and musculoskeletal imaging. The CXR Suite is the flagship portfolio combining three modules: ChestLink (world's first CE Class IIb certified autonomous AI for normal chest X-ray reporting with 99.9% sensitivity), ChestEye (CAD detecting 75 radiological findings with triage), and ChestEye Quality (real-time QA using NLP to detect missed findings). The CT Suite and MSK Suite extend this workflow-integrated AI approach into chest CT and musculoskeletal imaging respectively. All solutions are designed to integrate directly into existing PACS environments and support radiologists from study arrival through final report.

Differentiator

Problem solved

Functional benefit

Brands

  • CXR Suite: AI suite for chest X-ray workflows including ChestLink autonomous AI, ChestEye CAD, and Quality assurance tools supporting 75 findings.
  • CT Suite
  • MSK Suite
  • ChestEye
  • ChestLink

Products and services

  • CXR Suite Comprehensive chest X-ray AI suite combining ChestLink (autonomous reporting), ChestEye (CAD for 75 findings detection), and ChestEye Quality (real-time QA). Offers four workflow tiers from basic decision support to full autonomy for normal chest X-rays. Designed for hospitals, radiology departments, and diagnostic imaging centers.
  • ChestLink World's first and only CE Class IIb certified autonomous AI for healthy chest X-ray reporting. Automatically identifies high-confidence normal examinations with 99.9% sensitivity and generates final reports without radiologist involvement, removing them from the radiologist worklist. Can automate up to 40% of chest X-ray workflow in general hospital settings and up to 80% in preventive health check settings.
  • ChestEye AI CAD application that detects 75 common radiological findings in chest X-rays with an average AUC of 93%, including localization of suspicious areas and preliminary reporting. Includes a triage feature to prioritize time-sensitive cases. Targets hospitals and radiology departments seeking AI-assisted detection.
  • ChestEye Quality AI-powered second-reader quality assurance tool that analyzes medical images and radiologist reports to prevent diagnostic errors. Uses NLP to cross-reference radiologist findings with AI-identified findings, alerting radiologists to missed findings in near-real time. Works with chest X-ray, MSK X-ray, mammography, and CT images.
  • CT Suite Chest CT AI suite powered by CT Eye for detection, prioritization, and quality assurance. Assists radiologists in identifying pulmonary embolism, lung lesions, and lung consolidation in adult chest CT studies, with study prioritization and automated post-report quality checks. Designed for hospitals and radiology departments handling chest CT workflows.
  • CT Eye CE-certified AI tool for chest CT imaging that supports radiologists in detecting pulmonary embolism, lung lesions, and lung consolidation. Provides study prioritization and automated post-report quality checks using NLP to compare AI findings with radiologist reports.
  • MSK Suite Musculoskeletal X-ray AI suite powered by MSK Eye for fracture detection and quality assurance. Supports radiologists in identifying fractures, arthritis, osteoporosis, bone lesions, and other skeletal abnormalities across high-volume musculoskeletal imaging workflows.
  • MSK Eye CE-certified AI tool for high-volume musculoskeletal X-ray reporting supporting findings such as fractures, dislocations, degenerative changes, arthritis, osteoporosis, bone lesions, and post-surgical findings. Includes triage prioritization and automated post-report quality checks.

Quantifiable outcome

  • Automates up to 40% of chest X-ray reporting workflow in general hospitals; up to 80% in preventive health check settings
  • +8 more outcomes

Companies that use Oxipit

Customer profile

Named customers8 records

Segments4 records

Ideal customer profiles4 records

Oxipit technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Integration4 records

AI capability7 records

Feature7 records

Oxipit partnerships and signals

Strategic signal

Partnerships

13 partnerships are on record, tiered flagship, core and minor.

  • SectraflagshipOEM/ Whitelabel/ Licensing Partner · 15 April 2026Swedish medical imaging IT company Sectra completed the acquisition of Oxipit in April 2026 (agreement announced March 5, 2026). Oxipit operates as a dedicated AI development center within Sectra's Imaging IT Solutions operating area. Sectra gains ownership of ChestLink (first CE Class IIB-certified autonomous chest X-ray AI), CT Eye, and MSK Eye. The acquisition strengthens Sectra's vendor-neutral AI marketplace and broadens its AI portfolio for diagnostic imaging. Sectra paid upfront cash consideration plus contingent consideration tied to commercial and regulatory milestones.
  • German Medical InstitutecoreStrategic or Co-development Partner · 3 March 2026The German Medical Institute in Cyprus selected Oxipit as its chest X-ray AI partner following a structured clinical evaluation of three leading vendors across 700+ real-world cases. Oxipit CXR Suite was chosen for pathology detection (CAD), smart triage, and semi-autonomous pre-populated reports, integrated via Newton's Tree PACS platform.
  • Diagnostikum GroupcoreChannel Partner/ Reseller/ Distributor · 18 November 2025One of Austria's largest private radiology providers (275,000+ patients annually) selected Oxipit CXR Suite after rigorous multi-vendor evaluation on its own retrospective dataset. Deployment via deepc integration platform. Diagnostikum noted Oxipit's strongest overall performance for their outpatient setting where the majority of exams are normal.
  • Vestre Viken Health TrustcoreStrategic or Co-development Partner · 5 June 2025Norway's first pilot project for AI-powered thoracic X-ray imaging, led by Vestre Viken as part of a national AI procurement coordinated with Sykehuspartner and other regional health authorities. The pilot evaluates ChestLink in supervised mode with the goal of advancing toward autonomous clinical use. Vestre Viken represents a structured, multidisciplinary approach to AI implementation in clinical practice.
  • UnilabsflagshipChannel Partner/ Reseller/ Distributor · 17 February 2025European diagnostic services provider Unilabs selected Oxipit to deploy ChestLink and ChestEye throughout its European network following a comprehensive international evaluation process. Initial rollout starts in Portugal with option to extend across all Unilabs operations in Europe. Oxipit's AI streamlines chest X-ray reporting through automated triage and second-reading capabilities.
  • deepccoreTechnology or Integration · 25 June 2024Partnership integrates Oxipit's ChestLink, ChestEye, and ChestEye Quality into the deepcOS radiology AI platform. Healthcare institutions access Oxipit solutions through a single contract, billing, service, and support framework with full data protection and cybersecurity compliance.
  • FIDI (Fundação Instituto de Pesquisa e Estudo de Diagnóstico por Imagem)flagshipStrategic or Co-development Partner · 1 April 2024FIDI, one of Latin America's largest radiology service providers (400,000+ studies/month across 90+ sites in Brazil), deployed Oxipit's chest X-ray AI in emergency departments via the CARPL platform integrated with Philips Vue PACS. AI-generated annotations appear directly on images, supporting ER physicians who lack real-time radiologist access. Reduced turnaround times from 1 hour to 5 minutes at some sites.
  • BlackfordcoreTechnology or Integration · 22 November 2023Blackford, a strategic radiology AI platform with 100+ applications, integrates Oxipit's Quality application into its enterprise AI platform. Provides radiologists with an always-on AI second reader that flags potential missed findings by cross-referencing radiologist reports with AI image analysis.
  • CARPLcoreTechnology or Integration · 2 March 2023CARPL platform, the world's only US FDA-cleared and CE-marked vendor-neutral AI platform, makes Oxipit's full product portfolio available to healthcare institutions globally. CARPL provides single-user interface, single data channel, and single procurement channel for testing, deployment, and monitoring of Oxipit AI in clinical workflows.
  • AstraZenecaminorStrategic or Co-development Partner · 26 April 2022Oxipit and AstraZeneca conducted a joint pilot study deploying ChestEye Quality AI for improved pulmonary nodule detection in two major primary care centers in Lithuania. Analysis of nearly 50,000 chest X-ray images in 2021 detected 82 additional clinically relevant nodule findings, potentially identifying additional early instances of lung cancer.
  • ParasmedminorChannel Partner/ Reseller/ Distributor · 12 January 2021Nairobi-based Parasmed, founded by a senior radiologist from Oulu University Hospital (Finland), distributes Oxipit CXR AI products across Eastern Africa. Before commercial deployment, Parasmed partners with local high-level medical institutions to evaluate software performance using real-world clinical data, demonstrating AI workflow to local institutions.
  • Teleradiología de ColombiaminorChannel Partner/ Reseller/ Distributor · 24 August 2020Leading diagnostic imaging services provider in Colombia rolling out Oxipit AI solutions across its network, marking the first Oxipit deployment in Colombia with more announcements expected in Latin America.
  • Healthcare KonnectcoreChannel Partner/ Reseller/ Distributor · 6 January 2020Swiss medical distribution company Healthcare Konnect distributes Oxipit's ChestEye AI imaging suite to healthcare institutions in Nigeria. Partnership aims to improve detection of 75 pathologies including tuberculosis in one of Africa's largest markets, addressing severe radiologist shortages (only ~400 specialists for the entire population).

Scale indicators7 records

Recent moves6 records

Expansion highlights6 records

Oxipit competitors and assessment

Company assessment

Direct peers

  • Qure.ai: Qure.ai is a leading AI radiology company with chest X-ray and head CT solutions (qXR, qER). It competes directly with Oxipit in autonomous and CAD chest X-ray AI, with similar target customers and global deployments.
  • Lunit: Lunit develops AI for chest X-ray (Lunit INSIGHT CXR) and mammography, with FDA-cleared and CE-marked products. Directly comparable to Oxipit's CXR Suite in terms of modality, customer base, and go-to-market.
  • Aidoc: Aidoc provides AI-driven triage and detection across CT and X-ray modalities. Overlaps with Oxipit's CT Eye and triage features, serving similar hospital and radiology department customers.
  • Annalise.ai: Annalise.ai offers a comprehensive AI platform detecting 130+ findings on chest X-rays. Directly competes with Oxipit's ChestEye (75 findings) and targets similar radiology workflows globally.
  • VUNO: VUNO develops AI medical imaging solutions including chest X-ray (VUNO Med-Chest X-ray) and CT. Comparable to Oxipit's portfolio in modality coverage and global commercial expansion in Asia and beyond.
  • Delft Imaging: Delft Imaging develops AI for chest X-ray screening, particularly for tuberculosis. Comparable to Oxipit's emerging-market deployments (Nigeria, Eastern Africa) addressing similar radiologist-shortage problems.

Broad incumbents

  • Siemens Healthineers (AI Radiology): Siemens Healthineers offers AI-Rad Companion and other radiology AI embedded within its enterprise imaging solutions. Represents a broad incumbent competitor that bundles AI with PACS, similar to how Sectra now bundles Oxipit.
  • Philips (AI Imaging): Philips integrates AI imaging applications within its Vue PACS and enterprise imaging portfolio (e.g., Philips Algorithm Marketplace). Competes indirectly via platform partnerships where Oxipit is also deployed (e.g., FIDI/Philips Vue PACS).

Others

  • Blackford: Blackford operates a vendor-neutral enterprise AI platform for radiology with 100+ apps. It is both a distribution partner for Oxipit's Quality application and an indirect competitor via other AI offerings on its platform.

Emerging players

  • contextflow: contextflow offers AI for CT imaging (SEARCH Lung CT). Already a partnership collaborator with Oxipit at Leiden UMC for combined CT quality assurance, addressing similar clinical use cases.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

Oxipit social profiles

Digital presence

Oxipit compliance and trust

Trust signal

Compliance8 records

Oxipit financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Oxipit leadership team

Management profile

Number of profiles

Profiles11 records

Oxipit funding detail

Funding detail

Funding overview

Funding rounds3 records

Investors5 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Oxipit M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Oxipit

What does Oxipit do?

Oxipit develops CE-certified AI software for radiology, offering autonomous chest X-ray reporting (ChestLink), computer-aided detection of 75+ radiological findings (ChestEye), real-time quality assurance (ChestEye Quality), chest CT analysis (CT Eye), and musculoskeletal X-ray analysis (MSK Eye). Solutions integrate directly into existing PACS/RIS environments of hospitals, radiology departments, and diagnostic imaging networks to automate routine reporting, prioritize urgent cases, and flag missed findings. The company sells through direct enterprise sales, AI marketplaces, and regional distributors, and operates as a dedicated AI development center within Sectra following its April 2026 acquisition.

Is Oxipit a public or private company?

Oxipit is a private company. It is classified as corporate owned and is currently acquired.

When was Oxipit founded?

Oxipit was founded in 2017. It employs 11 to 50 people.

Where is Oxipit based?

Oxipit is headquartered in Vilnius, Lithuania, in the Europe region.

How does Oxipit make money?

Two revenue lines are on record. AI Medical Imaging Software Licenses are the primary driver. The others are platform Marketplace Distribution.

Who are Oxipit's main competitors?

Direct peers on record are Qure.ai, Lunit, Aidoc, Annalise.ai, VUNO and Delft Imaging. Broad incumbents are Siemens Healthineers (AI Radiology) and Philips (AI Imaging). Blackford is listed as an others. contextflow is listed as an emerging player.

Does Oxipit have an API?

No public API is recorded for Oxipit.

What industry is Oxipit in?

Oxipit's product category is Radiology AI Software. Its primary akta.pro industry code is HLAHABAJ, Radiology AI, CAD & Advanced Visualization Software, with a secondary code of HLACALAG, AI Orchestration & Imaging Analytics Platforms (Model Management/Triage). Its NAICS code is 5132 and its SIC code is 7372.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PR NewswireRadiation Dose Management Market worth $0.96 billion by 2031 - Exclusive Report by MarketsandMarkets™The radiation dose management market is projected to grow from $0.51 billion in 2026 to $0.96 billion by 2031, a CAGR of 13.3%. North America holds the largest share at 42.1% in 2025, and the cardiology segment is expected to see the highest growth. Asia Pacific is forecast to be the fastest-growing region.PR NewswireRadiation Dose Management Market worth $0.96 billion by 2031 - Exclusive Report by MarketsandMarkets™The radiation dose management market is projected to grow from $0.51 billion in 2026 to $0.96 billion by 2031, a CAGR of 13.3%. North America holds the largest share at 42.1% in 2025, and the cardiology segment is expected to see the highest growth. Asia Pacific is forecast to be the fastest-growing region.MorningstarAI Portable Chest X-ray Triage Device Market to Reach USD 900 Million by 2036, Driven by TB Screening Expansion and AI-Powered Point-of-Care DiagnosticsFuture Market Insights has published a market research report projecting the global AI portable chest X-ray triage device market to grow from USD 280 million in 2026 to USD 900 million by 2036, representing a CAGR of 12.4% and generating an incremental opportunity of USD 620 million over the forecast period. The report identifies handheld systems as the leading product segment at 44% market share and tuberculosis screening as the dominant AI application at 38%, driven by government and donor-funded screening programs, radiologist shortages, and demand for decentralized diagnostics. Key growth markets include India (14.8%), Nigeria (14.2%), and South Africa (13.7%), while the competitive landscape features companies including Qure.ai, Lunit, VUNO, Annalise.ai, Aidoc, Delft Imaging, and Oxipit.InvestorsinhealthcareLithuania: Sectra strengthens position as provider of advanced, regulatory-approved AI solutions for diagnostic imaging with acquisition of OxipitSweden-based Sectra has completed the acquisition of Lithuania-based Oxipit, a developer of autonomous AI for radiology and the creator of the first CE Class IIB-certified autonomous chest X-ray analysis solution. The deal strengthens Sectra's portfolio with Oxipit's ChestLink, the world's first autonomous AI for normal chest X-rays, and adds regulatory expertise for deploying autonomous AI at scale. Oxipit's team will operate as a dedicated AI development centre within Sectra's Imaging IT Solutions operating area.RadiologynewsSectra Acquires Oxipit to Advance Autonomous AI in RadiologySectra has completed the acquisition of Oxipit, a pioneer in autonomous AI for radiology that developed ChestLink—the first CE Class IIB certified autonomous chest X-ray analysis solution. The acquisition adds clinically validated autonomous AI capabilities to Sectra's portfolio, enabling a product that automatically identifies and clears high-confidence normal chest X-rays from radiologists' worklists. Sectra will further develop ChestLink as part of its vendor-neutral AI marketplace and broader AI strategy for diagnostic imaging.PR NewswireSectra completes Oxipit acquisition, accelerating autonomous AI in radiologySwedish medical imaging IT company Sectra has completed its acquisition of Oxipit, a radiology AI pioneer that developed the first CE Class IIB-certified autonomous chest X-ray analysis solution. The deal gives Sectra ownership of Oxipit's flagship product ChestLink, which automatically identifies and clears high-confidence normal chest X-rays from worklists, along with the regulatory expertise needed to deploy autonomous AI at scale. Sectra positions the acquisition as strengthening its vendor-neutral AI marketplace and advancing its leadership in diagnostic imaging AI amid rising imaging volumes and radiologist shortages.SectraQ&A – Oxipit acquisitionIn March 2026, Sectra announced an agreement to acquire Oxipit, UAB, a European medical AI company specializing in radiology imaging solutions, and finalized the acquisition in April 2026. Oxipit, based in Vilnius, Lithuania, offers AI tools for chest X-ray, chest CT, and musculoskeletal X-ray workflows, including both decision-support and autonomous AI capabilities. Sectra stated it acquired Oxipit to strengthen its clinical AI capabilities, gain access to proven technology and specialized expertise, and accelerate deployment of AI solutions across its global customer base.YahooSectra completes Oxipit acquisition, accelerating autonomous AI in radiologyInternational medical imaging IT and cybersecurity company Sectra has completed its acquisition of Oxipit, a pioneer in autonomous AI for radiology and developer of the first CE Class IIB-certified autonomous chest X-ray analysis solution. The acquisition gives Sectra ownership of ChestLink, Oxipit's flagship product that automatically identifies and clears high-confidence normal chest X-rays from radiologists' worklists, freeing them to focus on cases with higher disease probability. Sectra states the deal complements its vendor-neutral AI marketplace and positions the company to help healthcare providers manage rising imaging volumes and address staff burnout.SectraSectra completes Oxipit acquisition, accelerating autonomous AI in radiologySwedish medical imaging IT company Sectra has completed its acquisition of radiology AI pioneer Oxipit, announced on April 15, 2026, strengthening Sectra's portfolio of regulatory-approved AI diagnostic solutions. Oxipit's flagship product ChestLink holds CE Class IIB certification and autonomously clears normal chest X-rays from radiologists' worklists, reducing their workload while enabling them to focus on higher-risk cases. The acquisition adds clinical validation and regulatory expertise to Sectra's vendor-neutral AI marketplace, positioning the company to address rising imaging volumes and radiologist burnout.BebeezSectra completes Oxipit acquisition, accelerating autonomous AI in radiology – BeBeez InternationalSwedish medical imaging IT and cybersecurity company Sectra has completed its acquisition of Oxipit, a pioneer in autonomous AI for radiology and developer of the first CE Class IIB-certified autonomous chest X-ray analysis solution. With this acquisition, Sectra gains ownership of Oxipit's flagship product ChestLink, which automatically identifies and clears high-confidence normal chest X-rays from radiologist worklists. The move positions Sectra as a leader in regulatory-approved autonomous AI for diagnostic imaging, aiming to help healthcare providers manage rising imaging volumes and address staff burnout.